24-Apr-2024
Cellectis Unveils Groundbreaking Gene-Editing Advances
TipRanks (Mon, 22-Apr 5:27 PM ET)
Globe Newswire (Mon, 22-Apr 4:30 PM ET)
Globe Newswire (Wed, 10-Apr 4:30 PM ET)
Globe Newswire (Mon, 8-Apr 4:30 PM ET)
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.
As of April 24, 2024, CLLS stock price declined to $2.50 with 36,033 million shares trading.
CLLS has a beta of 6.12, meaning it tends to be more sensitive to market movements. CLLS has a correlation of 0.35 to the broad based SPY ETF.
CLLS has a market cap of $179.88 million. This is considered a Micro Cap stock.
Last quarter Cellectis S.A. - American Depositary Shares reported $2 million in Revenue and -$.36 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.06.
In the last 3 years, CLLS stock traded as high as $20.42 and as low as $.96.
The top ETF exchange traded funds that CLLS belongs to (by Net Assets): APIE, AVDE.
CLLS has outperformed the market in the last year with a return of +31.6%, while the SPY ETF gained +24.2%. However, in the most recent history, CLLS shares have underperformed the stock market with its stock returning -13.5% in the last 3 month period and -9.1% for the last 2 week period, while SPY has returned +4.6% and -2.7%, respectively.
CLLS support price is $2.48 and resistance is $2.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS stock will trade within this expected range on the day.